Find in Library

Heart failure (HF) is a heterogeneous syndrome, with progressive evolution and negative impact on quality of life and mortality of patients. The incidence of HF in Europe and the United States of America varies between 1 to 9 cases per 1000 inhabitants, depending on the population studied and the diagnostic criteria used1. Currently, it is estimated that approximately 64.3 million people suffer from HF world-wide2. One of the most important therapeutic goals for patients with HF is represented by maintaining and improving the quality of life. Many patients value functional status and quality of life more than longevity. The most important predictors of the quality of life in HF are the presence of symptoms and their severity, functional status and depression3. Current guidelines recommend the combined use of medical and behavioural interventions to improve the functional status of these patients.